Retro Biosciences emerges from stealth with $180M from Sam Altman

Retro Biosciences

MIT Technology Review revealed that OpenAI CEO Sam Altman had put $180 million—essentially all his liquid wealth—into Retro Biosciences, an anti-aging startup aiming to add 10 healthy years to human life. Led by Joe Betts-LaCroix, Retro works on plasma replacement, cellular reprogramming and restoring autophagy, the cellular waste-clearing process.

• Sam Altman committed $180 million of his personal liquid wealth to Retro Biosciences.
• Company aims to add 10 healthy years to average human lifespan through multiple research approaches.
• Focuses on plasma replacement therapy, cellular reprogramming, and autophagy restoration.
• Altman also invested $375+ million in fusion energy company Helion, demonstrating his strategy of backing hard-tech ventures.